Pharmacoeconomics and formulary decision making
- PMID: 10160112
- DOI: 10.2165/00019053-199600091-00005
Pharmacoeconomics and formulary decision making
Abstract
Pharmacoeconomic assessment of formulary actions has become increasingly common in local, national, and international formulary decision making. Tactics for managing medication use include formulary management and drug policies. Pharmacoeconomic data can provide support for these formulary decisions. For example, pharmacoeconomic data can support the inclusion or exclusion of a drug on or from the formulary and support practice guidelines that promote the most cost-effective or appropriate utilisation of pharmaceutical products. Various strategies can be used to incorporate pharmacoeconomics into formulary decision making. These include using published pharmacoeconomic studies and economic modelling techniques, and conducting local pharmacoeconomic research. Criteria for evaluating the pharmacoeconomic literature, suggestions for employing economic models, and suggested guidelines for conducting pharmacoeconomic projects are discussed. Although most formularies are viewed as cost-containment tools, formularies should not be a list of the 'cheapest' alternatives. Today's formulary should contain agents that optimise therapeutic outcomes while controlling cost. Pharmacoeconomic assessments of formulary decisions help to ensure that the agents promoted by our formularies yield the highest outcome per dollar spent. A discussion of the process for formulary action in a US hospital, the influence of pharmacoeconomics on US formularies, and strategies for incorporating pharmacoeconomics into formulary decision making are presented in this paper.
Similar articles
-
Application of pharmacoeconomics to formulary decision making in managed care organizations.Am J Manag Care. 2002 Feb;8(2):161-9. Am J Manag Care. 2002. PMID: 11858228 Review.
-
The use of pharmacoeconomic data in formulary selection.Top Hosp Pharm Manage. 1994 Jan;13(4):47-53. Top Hosp Pharm Manage. 1994. PMID: 10130683
-
Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.Pharmacoeconomics. 1992 Apr;1(4):265-81. doi: 10.2165/00019053-199201040-00004. Pharmacoeconomics. 1992. PMID: 10147017
-
Use of pharmacoeconomic data in making hospital formulary decisions.Am J Health Syst Pharm. 2002 Aug 1;59(15):1441-4. doi: 10.1093/ajhp/59.15.1441. Am J Health Syst Pharm. 2002. PMID: 12166044
-
Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature.Am J Health Syst Pharm. 1999 Aug 15;56(16):1630-8; quiz 1638-40. doi: 10.1093/ajhp/56.16.1630. Am J Health Syst Pharm. 1999. PMID: 10459385 Review.
Cited by
-
Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach.Curr Diabetes Rev. 2024;20(8):12-22. doi: 10.2174/0115733998246567230924134603. Curr Diabetes Rev. 2024. PMID: 37842896 Review.
-
Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.BMC Med Inform Decis Mak. 2012 Sep 27;12:110. doi: 10.1186/1472-6947-12-110. BMC Med Inform Decis Mak. 2012. PMID: 23016739 Free PMC article.
-
The effect of managed care on prescription drug costs and benefits.Pharmacoeconomics. 1999 Feb;15(2):129-40. doi: 10.2165/00019053-199915020-00002. Pharmacoeconomics. 1999. PMID: 10351187 Review.
-
Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.Pharmacoeconomics. 2002;20(1):9-21. doi: 10.2165/00019053-200220010-00002. Pharmacoeconomics. 2002. PMID: 11817989
References
MeSH terms
LinkOut - more resources
Full Text Sources